Edward Rustamzadeh
University of Minnesota
9 Papers
185 Citations
Edward Rustamzadeh is an academic researcher from University of Minnesota. The author has contributed to research in topics: Immunotoxin & Plasminogen activator. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model
Deborah A. Todhunter,Walter A. Hall,Edward Rustamzadeh,Yanqun Shu,Sekou O. Doumbia,Daniel A. Vallera +5 more
TL;DR: Findings indicate that bispecific IT may allow treatment of a broader subset of antigenically diverse patients while simultaneously reducing the exposure to toxin required than if two separate agents were employed.
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Edward Rustamzadeh,Walter A. Hall,Deborah A. Todhunter,Vincent D. Vallera,Walter C. Low,Haiying Liu,Angela Panoskaltsis-Mortari,Daniel A. Vallera +7 more
TL;DR: The results suggest that the DTAT recombinant fusion protein is highly effective in an intracranial model and DTAT might be an effective treatment for glioblastoma.
47
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme
TL;DR: This article reviews the progress to date with DTAT, a recombinant fusion protein targeting the urokinase-type plasminogen activator receptor (uPA) and delivering a potent catalytic toxin that caused the regression of small subcutaneous uPAR-expressing tumors with minimal toxicity to critical organs.
37
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13
Edward Rustamzadeh,Daniel A. Vallera,Deborah A. Todhunter,Walter C. Low,Angela Panoskaltsis-Mortari,Walter A. Hall +5 more
TL;DR: The studies show that DTAT13 has properties encompassing those of both DTIL13 and DTAT and warrants further consideration for clinical development.
30
Immunotoxin therapy for CNS tumor.
TL;DR: The history, design, toxicity, and pharmokinetics of immunotoxins will be discussed in detail and the prognosis of these malignant tumors still remains poor.
30